340B And Price Negotiation: US Medicare Washes Its Hands Of The Issue

The US Centers for Medicare and Medicaid Services is counting on “good faith” between manufacturers and covered entities to ensure appropriate 340B pricing is offered on drugs subject to the new negotiation authority.